- Company’s
product distribution is expected to reach a wider customer base in the
United States
- ETST
is working to expand its distribution footprint in Latin America
- Company
reports successes for all four wholly owned subsidiaries
Biotech company Earth Science Tech Inc. (OTCQB: ETST), focused on the
nutraceutical and pharmaceutical fields, is taking strategic steps in
anticipation of a projected $16 billion market in the United States by the year
2025 (http://ibn.fm/kkkaT).
The company is increasing the size of its sales team and
expanding its full-spectrum cannabidiol (CBD) product distribution. ETST
continues to offer the highest purity and quality high-grade, full-spectrum CBD
oil on the market, which has led to inquiries from other brands. This presents
a great deal of opportunity on the horizon for the company, including a Latin
American distribution partnership and High Grade Full Spectrum Iq2 CBD shots.
ETST is working with its manufacturing partner to launch a
white labeling initiative. This move will allow marketers to rebrand the ETST
High Grade Full Spectrum CBD line. ETST has already received a large number of
white labeling inquiries, thus allowing the company to capture additional
market share.
Product distribution is expected to reach a larger customer
base in the U.S. thanks to recent agreements with CannaBiz and Dessert Sun
Distribution (http://ibn.fm/MQAcd).
These companies will provide pharmacies, chiropractors, dispensaries, athletic
clubs and clinics throughout the States with access to ETST’s CBD products.
However, according to ETST Chief Sales Officer David Burbash, these
distribution agreements, while important, only represent a fraction of the
opportunities that lay ahead.
In January, ETST announced that it had partnered with
Forzagen, a premium dietary supplement provider, to distribute CBD products
throughout Mexico and South America (http://ibn.fm/xggiC). This partnership gives Forzagen
exclusivity for Latin American distribution. ETST anticipates additional
revenue and increased exposure, as Forzagen’s distribution network includes
placement in large retailers such as Sam’s Club and Petco.
ETST is establishing itself as a world leader in the CBD
space through four wholly owned subsidiaries:
- Earth
Science Pharmaceutical Inc. (http://ibn.fm/ib1So) works to create low-cost,
noninvasive diagnostic tools, medical devices, testing processes and
vaccines for sexually transmitted infections and diseases. Hygee is the
company’s first medical device, first launched in Vietnam, and is
providing women with a discreet home testing solution for chlamydia.
- Cannabis
Therapeutics Inc. (http://ibn.fm/agycG)
is committed to the discovery and development of leading-edge,
cannabinoid-based pharmaceutical and nutraceutical products. Currently,
the company is developing treatments for breast and ovarian cancers. This
focus is part of a larger commitment by ETST to improve the health of
women around the world.
- KannaBidioiD
Inc. (http://ibn.fm/d8S7v)
focuses on developing recreational CBD products, such as infused vapes and
e-liquids, as well as assisting with nicotine reduction therapy.
- Earth
Science Foundation Inc. (http://ibn.fm/lDowX) is currently working toward
nonprofit status. The purpose of the foundation is to provide ETST CBD
products to people in need who are dealing with cancer, epilepsy, autism,
chronic pain and depression.
ETST is fully compliant with the federal farm bill and is
able to legally ship products to all 50 states.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates
relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
